Background Childhood illness can impose significant costs and health strains on family members, but these are not routinely captured by pediatric economic evaluations. This review investigated how family "spillover effects" related to costs and health outcomes are considered in pediatric cost-utility analyses (CUAs). Methods We reviewed pediatric CUAs published between 2000 and 2015 using the Tufts Medical Center Cost-effectiveness Analysis (CEA) Registry and the Pediatric Economic Database Evaluation (PEDE) Registry. We selected studies conducted from the societal perspective and included in both registries. We investigated how frequently family spillover was incorporated into analyses, and how the inclusion of spillover health effects and costs changed CUA results. Results We found 142 pediatric CUAs meeting inclusion criteria. Of those, 105 (72%) considered either family spillover costs (n = 98 time costs, n = 33 out-of-pocket costs, n = 2 caregiver healthcare costs) or health outcomes (n = 15). Twenty-four studies included 43 pairs of incremental cost-effectiveness ratios (ICERs) with and without spillover. In 19 pairs of ICERs, adding spillover changed the ICER enough to cross a common cost-effectiveness threshold (i.e., $50,000/QALY, $100,000/ QALY, $150,000/QALY; values are in 2016 US$). Incorporating spillover generally made interventions more cost-effective (n = 18; 42%), or did not change CUA results enough to cross a threshold (n = 24; 56%). Including family spillover reduced ICERs by 31% ($40,000/QALY) on average. Conclusion Most pediatric CUAs conducted from a societal perspective include family costs but fewer include family health effects. Inclusion of family spillover effects tends to make CUA results more favorable. Future pediatric CUAs should aim to more fully incorporate the family burden of illness.
Introduction
Internationally, many interventions undergo economic evaluation prior to being funded by public or private payers. Guidelines that specify how these economic evaluations should be conducted, and what information should be included, have evolved over time. In particular, US guidelines for cost-utility analyses (CUAs), the most common form of economic evaluation performed in healthcare, were first established in 1996 with the US Panel on Costeffectiveness in Health and Medicine [1] . These guidelines specified that all costs and health outcomes associated with an illness or intervention should ideally be included for CUAs conducted from a societal perspective, including family costs and health outcomes [1] . However, the authors acknowledged that limited data were available at that time on the health-related quality-of-life (HRQOL) of family members, so recommended that these family health effects be included in sensitivity analyses, when possible [1] . In the 20 years since those guidelines were published, however, there has been a growth in the literature on both family cost and health impacts during patients' illness and treatment. Reflecting this context, updated guidelines from the Second US Panel on Cost-effectiveness in Health and Medicine recommend that both family costs and health outcomes should be included in CEAs conducted from a societal perspective [2] . Current economic evaluation guidelines from Canada [3] , the UK's National Institute for Health and Care Excellence (NICE) [4, 5] , and the Netherlands [6] also recommend the inclusion of these family cost and health "spillover effects," when relevant.
As these guidelines evolved, most CUAs have focused on the health and cost outcomes of the patient alone [7] . This narrow framework may significantly underestimate the true burden of many illnesses that have a large family impact, such as those in children [8, 9] . Previous research has shown that parents of ill children with cancer or depression report significantly lower HRQOL compared to spouses of adults with these same illnesses [10] . Caring for a chronically ill child has been associated with a higher risk of parents developing anxiety and depression [11] . This health and economic burden can extend beyond caregivers to other family members, who suffer decreased HRQOL [10, 12] . Childhood illness is also associated with parental employment loss, and other financial burden [13, 14] . Conversely, parents can experience a positive utility from caregiving [15, 16] .
Two previous reviews have looked at the inclusion of family spillover in CUAs, but neither has focused on pediatric interventions. Krol et al. examined 100 CUAs in four disease areas published from 2008 to 2013 [7] . They found that the majority of studies for Alzheimer's disease (64%) included some type of family spillover, compared to 14% in rheumatoid arthritis, 13% in Parkinson's disease, and 0% in metastatic colorectal cancer [7] . The inclusion of spillover costs and health effects had limited impact on cost-effectiveness results in most studies [7] . Goodrich et al. reviewed 30 economic evaluations published in 1990-2010 across a range of disease areas and found that the inclusion of informal care did not have a clear positive or negative impact on the results of the economic evaluations in their study [17] .
To date, however, no studies have systematically reviewed family spillover in CUAs for child health interventions, which is an important area to study given the known family burden of childhood illness. It is important to determine the extent to which pediatric CUAs include family spillover effects and implications regarding the reported cost-effectiveness of child health interventions. Identifying current strengths and weaknesses in the literature base can inform best practices in this field moving forward. This study aimed to determine: (1) how often pediatric CUAs conducted from the societal perspective include family cost or health outcomes (i.e., family spillover effects); (2) the characteristics of studies (i.e., country of study, disease area, intervention type) that do and do not include family costs or health outcomes; and (3) how cost-effectiveness results change within studies when family spillover costs or health outcomes are included/excluded.
Methods

Selection of Studies and Data Collection
We conducted searches of the Tufts Medical Center Costeffectiveness Analysis (CEA) Registry (www.ceare gistr y.org) and the SickKids Pediatric Economic Database Evaluation (PEDE) Registry (pede.ccb.sickkids.ca/pede/ index.jsp) for CUAs of interventions aimed at children aged 0-18 years [18] [19] [20] . The Tufts CEA Registry contains detailed information on cost per quality-adjusted lifeyear (QALY) analyses published through 2016. The search protocol and inclusion criteria for the Tufts CEA Registry are detailed elsewhere [21, 22] . Briefly, the procedure starts in MEDLINE with a search for English-language articles using the keywords "QALYs," "quality-adjusted," and "cost-utility analysis." Following this, abstracts are screened for original studies containing cost per QALY results. Selected abstracts undergo full paper review by two independent reviewers who extract information for inclusion in the Registry on: study methods, incremental costeffectiveness ratios (ICERs) and preference-based (i.e., "utility") HRQOL weights. The PEDE database includes pediatric economic evaluations published between 1980 and 2016, including CUAs. The studies included in the PEDE database are selected from a search of a broad range of databases, including MEDLINE, EMBASE, CINAHL, IPA, EconLit ERIC, EBM Cochrane Collection, University of York's Center for Reviews and Dissemination, as well as over 70 health technology assessment, academic, and government web sites. Selected abstracts are reviewed and data variables relevant to health economic evaluation are extracted and included in the PEDE database.
We selected CUA studies published between 2000 and 2015 because this was the most current year of studies contained in both the Tufts CEA Registry and PEDE at the time of this review. We selected only analyses conducted from a societal perspective and contained in both registries. We chose to focus on the societal perspective as these studies would be expected to include both family cost and QALY outcomes, whereas studies conducted from the healthcare perspective would not be expected to include certain elements of spillover, including parent time costs.
These two registries were used in combination as the PEDE Registry provided easy identification of all pediatric CUAs, while the Tufts CEA Registry contained additional information about each article. We identified a total of 163 studies that met our inclusion criteria for full review. During full review articles were excluded if: (1) the article was focused on a prenatal population, (2) the intervention was targeted toward the parent, and not specifically aimed at the child, or (3) there was not enough information clearly presented in the article to determine if family spillover was included (Online Appendix Fig. A1 ). In total, our final analysis included 142 CUAs.
Two trained readers (B.D. and B.M.) independently reviewed each article and recorded data using a standardized data collection form developed in REDCap [23] . Readers collected information on whether or not the study considered family spillover health effects or costs, the types of health effects or costs included, and the method of incorporating spillover into the ICER (Table 2) .
Family spillover can include costs and health effects for parents, siblings, and extended family members. We considered spillover costs to include: (1) extra costs incurred by family members specifically for the purposes of caring for a sick child (e.g., opportunity time costs which could be valued as lost leisure or work time to care for a child, or out-of-pocket costs such as for transportation to doctor's visits), or (2) additional healthcare costs for family members who became ill as a direct result of caring for or about a sick child. We considered spillover health effects to be the impact of a child's illness on the HRQOL or health (e.g., prevalence of anxiety, depression) of family members. This could be conveyed as a parent's QALYs loss, for example. For infectious disease studies, we did not consider secondary infection of family members to be a spillover health effect.
The two readers convened weekly for a consensus audit to review study data abstraction and resolve discrepancies. Any conflicts that could not be resolved during consensus were brought to larger team meetings for a final group decision.
Analysis
We examined the frequency with which family spillover costs and health effects were considered in pediatric CUAs, and how these effects were incorporated into analyses. We summarized the characteristics of pediatric CUAs with and without spillover costs or health effects. In addition, we investigated the impact that incorporating family spillover had on the study's reported ICER. Specifically, within a study, we compared ICERs that included family spillover costs or health effects with corresponding ICERs that did not incorporate these spillover effects. Where those comparisons were not reported by the author but disaggregated costs and QALY losses were, we re-calculated the ICERs by including/excluding spillover values. We compared withinstudy ICER pairs with and without spillover. We recorded whether including spillover costs or health effects resulted in a higher or lower ICER that crossed conventional US CEA thresholds (i.e., cost-saving; $50,000/QALY; $100,000/ QALY; $150,000/QALY) [24] . We explored the impact of spillover on the reported ICERs in the overall sample and in a subset of studies focusing on rotavirus vaccine (the most commonly considered intervention among studies we evaluated). When possible, we also explored the impact of independently including either spillover costs or spillover health effects in the analysis. All ICERs were converted to 2016 US dollars using currency exchange rates and the consumer price index (https ://www.bls.gov/cpi/).
Results
We identified 404 CUA studies in both the PEDE and CEA Registry. We excluded 241 studies not conducted from a societal perspective. Of the remaining 163 studies that met our inclusion criteria for full review, 21 articles were further excluded according to our exclusion criteria; our final analysis included 142 CUA studies (Online Appendix Fig. A1 ).
The majority of these studies focused on infectious diseases (n = 83, 58%; Table 1) , with rotavirus being the most common disease studied (n = 18). Vaccines were the most common intervention type studied (n = 74, 52%), followed by pharmaceuticals (n = 30, 21%). Most of the pediatric CUAs focused on primary prevention strategies (n = 86, 61%; Table 1 ). Sixty (42%) of the CUAs were US studies, followed by 25 (18%) from the Netherlands. The studies were funded mainly by government or foundations (n = 54, 38%), or industry (n = 43, 30%).
We found that 105 pediatric CUAs (72%) considered either the spillover costs (n = 98 time costs, n = 33 out-ofpocket costs, n = 2 caregiver healthcare costs) or health effects (n = 15) of family members, and this trend was fairly consistent over time from 2000 to 2015 (Table 1) . Studies of treatment interventions (tertiary prevention) included spillover more frequently (88%) than those focused on primary or secondary prevention (70% and 68%, respectively). Studies originating from the Netherlands and the UK, although less common than studies from the USA, included spillover more frequently (92%, Other types of out-of-pocket costs included: babysitting, day care, parking, special foods, diapers, hotel, over-the-counter medications c Includes: (1) 'corresponding annual indirect costs due to direct medical costs of the mother' in ADHD study [25] and (2) 'healthcare costs of mothers of children with ADHD' [26] d Other ways spillover effects were included: (1) the values of QALY losses took into account both the child's and the parent's pain and suffering and the family's inconvenience from the disease in a single number [48] ; (2) quality adjustments were included in the model as a one-time decrement in utility for each temporary health state. For example, an episode of influenza results in a one-time loss of 0.005 QALY. Utility losses were calculated by dividing the discounted time traded off by the respondent's discounted life expectancy. Quality adjustments include health-related quality-of-life for child and parent as well as productivity losses for parents [49] Including spillover QALYs (n = 15) Netherlands; 100%, UK; 70%, USA). The inclusion of spillover by other study characteristics is summarized in Table 1 . All of the CUAs that included spillover health effects and costs considered the effects for family caregivers (i.e., parents). No studies considered spillover on non-caregiving family members (i.e., siblings) or informal caregivers outside of the family.
There was a wide variation of the type of spillover costs that were incorporated into CUAs (Table 2) . Most studies incorporated a cost for time spent caring for a sick child (n = 98; 93%), with most studies including this as a productivity loss for missed time at work (n = 87), commonly valued based on wage rate. Roughly one-third (n = 33; 31%) considered out-of-pocket costs, most commonly for medical visit transportation (n = 28; 27%). Two studies (2%) included direct healthcare costs related to the ill health of a caregiver as a result of caring for a sick child [25, 26] . Most studies (n = 73; 70%) that included spillover costs included only one type of cost.
A QALY loss of a caregiver was the only type of spillover health effect included in the ICERs of CUAs we reviewed ( Table 2 ). The EQ-5D was the utility elicitation method most frequently used (n = 12; 80%). Other methods like the time trade off or visual analog scale were used much less frequently (n = 2).
The most common method for incorporating spillover cost or health effects into the ICER was to add caregiver values to patient values. In studies that considered spillover costs (n = 94), 90% added caregiver costs to patient costs; in studies that considered health effects (n = 10), 67% added caregiver QALY loss to patient QALYs using a time horizon specific to the patient's illness. Two studies included a QALY loss that was calculated by considering the joint QALY loss to both the caregiver and the patient together, rather than valuing them separately and then adding them together as did the other studies.
Impact on ICERs
The 142 CUAs reported a total of 354 ICERs: 91 (26%) costsaving; 182 (51%) below $150,000/QALY, and 56 (16%) over $150,000/QALY or dominated (higher costs and less effective). Using 43 pairs of ICERs from 24 studies, we recalculated these ICERs with and without spillover effects and found that incorporating the spillover cost and/or health effects available for the study generally made interventions more favorable in terms of cost-effectiveness ( Fig. 1 ; data available as Online Supplementary Material). We were only able to compare ICERs where authors reported two ICERs for a given intervention (one with spillover and one without spillover) or when the authors provided disaggregated costs and QALY values that allowed us to recalculate the [26] ICERs with and without spillover. In 11 cases (26%), including spillover effects made the intervention cost-saving, or remain cost-saving. In the remaining cases, ICERs were reduced by 31% ($40,000/QALY) on average by including spillover effects. In 18 cases (42%) a reduction in the ICER crossed a common CEA threshold, most commonly going from an ICER above to below thresholds of $50,000/QALY or $100,000/QALY (Table 3 ). In 24 cases (56%), including spillover effects did not change the ICER enough to cross a CEA threshold. In only one case (2%) did the inclusion of spillover make the intervention less favorable by common CEA standards. In this one case, the cost-effectiveness of the intervention, for acute otitis media, became less favorable when parent productivity loss estimates and out-of-pocket costs had a greater impact on the costs of an intervention of watchful waiting versus a comparator of delayed prescription treatment. This spillover increased the cost difference between the intervention and the comparator, compared to a scenario without spillover costs, and the resulting ratio became less favorable.
Where the appropriate disaggregate data were provided, we recalculated ICERs independently with just spillover 
No Spillover vs. Spillover Health Effects Only
No Spillover Spillover Health Effects Only health effects from two studies ( Fig. 2 ; just spillover costs from 17 studies, Fig. 3 ; and both spillover costs and health effects from two studies, Fig. 4 ). We generally found that including one type of spillover made the ICER more favorable than omitting spillover altogether. However, from our small sample size, we were unable to conclude whether the inclusion of spillover costs or QALYs had a greater impact on this change. To control for known variation in studies by illness, intervention type, and comparator, we reviewed 36 ICERs from 18 studies that assessed the cost-effectiveness of rotavirus vaccine (the most commonly considered intervention among studies we evaluated) compared with no vaccine. As a case study, we recalculated 21 of those ICERs from 12 studies [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] that had enough information to compare them with and without spillover effects included (Online Appendix  Fig. A2 ). In three cases (14%), including spillover made the rotavirus vaccine cost-saving. In the remaining cases, the ICERs were on average reduced by 47% ($62,000/QALY) by including spillover. Two rotavirus studies allowed us to evaluate the impact of including spillover health effects only, spillover costs only, or both types of spillover into analyses 
No Spillover vs. Spillover Costs & Health Effects
No spillover Spillover costs & health effects [28, 29] , but it was not clear in these analyses whether including spillover health effects or costs had the biggest impact on the results (Online Appendix Fig. A3-A4 ). These trends are consistent with those observed in the overall sample across various diseases and interventions.
Discussion
For CUAs to truly be conducted from a societal perspective, analyses should fully account for the costs and health outcomes associated with interventions, which includes spillover on family members. Despite the known family burden that accompanies childhood illness, we found a majority of pediatric CUAs conducted from a societal perspective included some family costs, but only a small fraction included parent or other family health outcomes. We found that there has been a consistent effort to incorporate some type of family spillover consistently over time. Costeffectiveness studies of treatment interventions are more likely than those focusing on primary or secondary prevention to incorporate spillover. This may be because the family impact is immediate in these cases and including spillover will likely have a greater impact on results.
When studies did account for any type of family spillover, ICERs were reduced by 31% ($40,000/QALY) on average. Including spillover made the cost-effectiveness results more favorable at common CEA thresholds in about 40% of cases. Our findings build on previous reviews in other disease areas that reported mixed results to show that spillover can have an important and favorable effect on the reported cost-effectiveness of child health interventions [17, 39] .
No studies in our review fully accounted for family spillover by including the range of family outcomes that are likely associated with a child's illness: family QALY impacts, caregiving time costs, family out-of-pocket costs, and potential direct healthcare costs for a health condition, such as depression or anxiety, resulting from a family member's illness. The majority of studies in our review included only one component of family cost, most commonly caregiving time costs. Similarly, only a small fraction of the studies included a QALY loss for caregivers.
Studies that did incorporate caregiver QALY losses into the analysis typically did so using the EQ-5D instrument. This instrument measures preference-based HRQOL based on five domains: mobility, self-care, usual activities, pain/ discomfort, and anxiety/depression [40] . Although previous studies have demonstrated that the EQ-5D has adequate validity when administered to caregivers of children with autism and meningitis, more work is needed to determine if this holds true for other childhood illnesses [41, 42] . The EQ-5D may not adequately capture components of HRQOL most relevant to caregivers. The EQ-5D has only one question related to mental health (anxiety/depression), which is an important element of family spillover [43] . Qualityof-life instruments, including the CarerQol [44] and Carer Experience Scale [45] , have been developed to capture the relevant aspects of caregiving burden, such as fulfillment and financial problems. However, these instruments do not capture the full health-related burden of caregiving and do not produce health utility values that can be used to generate QALYs.
Direct elicitation techniques such as the time trade-off and visual analog scale may provide more flexibility in capturing the HRQOL burden of caregiving as they are not elicited based on specific domains. However, one important consideration is the fact that it may be difficult for parents to disentangle their own wellbeing from their child's wellbeing when answering direct elicitation questions, such as the time they would be willing to trade to improve their child's health [46] . This may be particularly problematic when parents are presented with a direct elicitation question that is intended to capture their own preference-based HRQOL, and are also separately asked to value improvements in their child's HRQOL. In these cases, parents may consider their own health when asked to consider a health improvement for their child, or vice versa consider their child's health when considering a health improvement for themselves [46, 47] . Combining these two estimates from direct elicitation methods, therefore, risks double counting child and parent health. This problem with direct elicitation of spillover may potentially be avoided by asking parents to value their own and their child's health together in a single question. Two studies in our review derived utility values in this manner [48, 49] .
No studies in our review included QALY losses for family members who were not caregivers. The literature distinguishes "caregiving effects" from "family effects" when describing HRQOL spillover impact in families [50] . The caregiving effect relates to the HRQOL impact of providing care to the patient [7, 9, 51] , while the family-effect relates to the impact of caring about a sick individual [50, 52] . Previous research has shown that the family effect may be a stronger determinant of HRQOL than the caregiver effect [10, 53] , and that it may extend to more than one close family member [39] . As a result, excluding the HRQOL burden on non-caregiving family members (such as siblings) likely leads to an underestimation of the true burden of the illness and of the potential value of an intervention that may relieve this burden. As broader spillover effects are considered, methods will need to evolve to adequately capture these impacts into ICERs. We found that the most common method currently used to incorporate caregiver QALY loss into the calculation of the ICER is simply subtracting the caregiver QALY loss from the overall child-specific QALY difference. This method will likely not be appropriate as the burden of multiple family members is incorporated into analyses. Previous work in this area has proposed the use of a multiplier effect of health impacts to incorporate the broader impact of a patient's illness on one or more family members, but future work in this area is needed [54] .
In addition, no studies in our review considered spillover impacts on family members related to the loss of a child. Current standards limit analyses to the duration of the primary individual's life expectancy, and grief-related spillover extends past this time frame. However, the magnitude of this grief-related spillover is likely substantial, and there has been some preliminary work in this area [55] [56] [57] . Two studies conducted in the USA reported an increase in prescription costs and psychotherapy services among parents following a child's death [56, 57] . One study found that the health utility of adults who had experienced a loss from suicide in their life was significantly lower than those without this experience [55] . Future work is needed to measure griefrelated spillover on family members in other contexts, and propose methods to incorporate it into CUAs.
Previous work has highlighted the important considerations in conducting CUAs for child health interventions, including family spillover [46, 58] . Many of these considerations have over time been incorporated into international CUA guidelines. However, our results indicate that there remains substantial variation in how these guidelines are implemented in practice (i.e., what family costs are included in the CUA, and how family QALYs are measured and incorporated into the analysis). These variations can have important implications for CUA results, and more detailed guidance is needed on when and how specific components of spillover should be included in CUAs. These guidelines may apply broadly to a range of illnesses that have close family involvement. For children specifically, there is a need for guidance on how spillover should be incorporated over the life course when relevant, particularly as the role of caregiving may shift from parents to siblings and other family members as the child grows. In addition, spillover for childhood illness can be more complicated to measure than in adults because children already require caregiving, and the spillover aspect of their illness must be incremental to parents' typical caregiving tasks. Some previous analyses have measured this spillover by measuring cost and quality-of-life outcomes in parents of children with and without illness, to calculate the additional burden of caregiving [59] , but specific guidance in this area is needed.
Our review is limited by the information provided by the authors in the published papers included in our review. For example, if a paper stated that caregiver time was valued as an opportunity cost, we were unable to explain an exact valuation method beyond this. Our results are reflective of the interventions and comparisons included in the studies. Our analysis of the change in ICERs when spillover effects are included or excluded was necessarily restricted to studies in which family outcomes could be disaggregated from patient outcomes. The small number of studies that allowed this disaggregation restricted our ability to further stratify these analyses by intervention type or other variables of interest. Finally, we restricted our review to CUAs conducted from the societal perspective. This perspective is the only one where family spillover can be presented both in terms of costs and QALYs. Studies conducted from other perspectives, such as the healthcare perspective, should likewise include family QALY loss when relevant, but will be more limited in their inclusion of family costs that are not healthcare-related.
Conclusions
Despite the significant family impacts of childhood illness, many pediatric CUAs conducted from a societal perspective do not fully incorporate family spillover effects into the analysis, despite recommendations to do so. As a result, these analyses may undervalue the true burden of childhood illness and interventions for illnesses. Future studies of child health interventions conducted from the societal perspective should work to more fully incorporate family burden of illness and treatment, including both cost and HRQOL impacts on parents and other family members.
